CTC levels as a surrogate endpoint for clinical trials in mCRPC

A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …

PROs and HRQoL among patients participating in the LATITUDE trial

A newly published paper in The Lancet Oncology has provided early data from the LATITUDE trial on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) for men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer. … READ MORE …

PSA velocity no better than latest PSA value in screening men carrying BRCA1/2 genes

Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …

Broad Institute launches the Metastatic Prostate Cancer Project

Last May we had told you about an initiative at the Broad Institute in Cambridge, Massachusetts, designed — initially —  to generate a comprehensive database of advanced prostate cancer treatment results based on the genetics of individual patients and their tumors. … READ MORE …

Prostate cancer projections for 2018

The American Cancer Society (ACS) has just announced its annual projections for cancer incidence and mortality rates for 2018. … READ MORE …

Is Retzius-sparing radical prostatectomy the surgical wave of the future?

Back in the early 1980s, Dr. Patrick Walsh at the Johns Hopkins Medical Center in Baltimore changed the nature of surgical treatment for prostate cancer when he first started to conduct so-called nerve-sparing radical prostatectomies. … READ MORE …

When can ADT be safely avoided with salvage radiation therapy?

Two randomized clinical trials (GETUG-AFU-16 and RTOG 9601) proved that adding at least some ADT to salvage radiation (SRT) improved outcomes. “Some ADT” was 6 months of goserelin acetate in the GETUG-AFU-16 trial, and 2 years of bicalutamide in the RTOG 9601 trial. … READ MORE …